17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==Surgical therapy== | ==Surgical therapy== | ||
* | *17-beta-hydroxysteroid dehydrogenase deficiency has a 28 % risk of germ cell tumor in disorder of sexual development. Consequently, close monitoring is warranted for an individual who is raised as a male rather than removing the gonads at the time of diagnosis.<ref name="urlThe Clinical and Molecular Heterogeneity of 17βHSD-3 Enzyme Deficiency - FullText - Hormone Research in Paediatrics 2010, Vol. 74, No. 4 - Karger Publishers">{{cite web |url=https://www.karger.com/Article/Fulltext/318004 |title=The Clinical and Molecular Heterogeneity of 17βHSD-3 Enzyme Deficiency - FullText - Hormone Research in Paediatrics 2010, Vol. 74, No. 4 - Karger Publishers |format= |work= |accessdate=}}</ref> | ||
*[[Surgical]] [[treatment]] can also be used to treat [[anatomic]] changes due to the [[hormonal]] [[disorder]]. Patients with this disease may present with [[ambiguous]] or [[female genitalia]], despite most of them developing male [[gender]] [[identity]]. | *[[Surgical]] [[treatment]] can also be used to treat [[anatomic]] changes due to the [[hormonal]] [[disorder]]. Patients with this disease may present with [[ambiguous]] or [[female genitalia]], despite most of them developing male [[gender]] [[identity]]. | ||
*Some studies have suggested that early surgical treatment may improve outcomes. [[Feminizing]] [[genitoplasty]] usually requires less [[surgical]] [[interventions]] than [[masculinizing]] [[genitoplasty]]. Outcomes vary greatly in both cases. Many patients may present with risk of [[neoplasia]] associated with the [[neovagina]], while regarding the masculinizing genitoplasty's results are heavily associated with the amount of [[erectile tissue]] and degree of [[hypospadias]].<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | *Some studies have suggested that early surgical treatment may improve outcomes. [[Feminizing]] [[genitoplasty]] usually requires less [[surgical]] [[interventions]] than [[masculinizing]] [[genitoplasty]]. Outcomes vary greatly in both cases. Many patients may present with risk of [[neoplasia]] associated with the [[neovagina]], while regarding the masculinizing genitoplasty's results are heavily associated with the amount of [[erectile tissue]] and degree of [[hypospadias]].<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | ||
Revision as of 08:03, 20 October 2022
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
Surgical therapy is guided by the risk of germ cell tumor development and to allow for proper gender assignment.
Surgical therapy
- 17-beta-hydroxysteroid dehydrogenase deficiency has a 28 % risk of germ cell tumor in disorder of sexual development. Consequently, close monitoring is warranted for an individual who is raised as a male rather than removing the gonads at the time of diagnosis.[1]
- Surgical treatment can also be used to treat anatomic changes due to the hormonal disorder. Patients with this disease may present with ambiguous or female genitalia, despite most of them developing male gender identity.
- Some studies have suggested that early surgical treatment may improve outcomes. Feminizing genitoplasty usually requires less surgical interventions than masculinizing genitoplasty. Outcomes vary greatly in both cases. Many patients may present with risk of neoplasia associated with the neovagina, while regarding the masculinizing genitoplasty's results are heavily associated with the amount of erectile tissue and degree of hypospadias.[2]
References
- ↑ "The Clinical and Molecular Heterogeneity of 17βHSD-3 Enzyme Deficiency - FullText - Hormone Research in Paediatrics 2010, Vol. 74, No. 4 - Karger Publishers".
- ↑ Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G (1990). "Lipid composition of outer stratum corneum and nails in atopic and control subjects". Arch Dermatol Res. 282 (8): 549–51. doi:10.1007/BF00371952. PMID 2082839.